The Tradeoff Between Shorter and Longer Courses of Dual Antiplatelet Therapy After Implantation of Newer Generation Drug-Eluting Stents

ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting

(2015) S. Schulz-Schupke et al.   EUROPEAN HEART JOURNAL

Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction

(2015) Robert W. Yeh et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin

(2015) Martine Gilard et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials

(2015) Tullio Palmerini et al.   LANCET

Balancing the Risks and Benefits of Dual Platelet Inhibition

(2015) John F. Keaney   NEW ENGLAND JOURNAL OF MEDICINE

Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction

(2015) Marc P. Bonaca et al.   NEW ENGLAND JOURNAL OF MEDICINE

Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials

(2015) E. P. Navarese et al.   BMJ-British Medical Journal

Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials

(2015) E. P. Navarese et al.   BMJ-British Medical Journal

Stent Thrombosis

(2014) Bimmer E. Claessen et al.   JACC-Cardiovascular Interventions

Second-Generation Drug-Eluting Stent Implantation Followed by 6- Versus 12-Month Dual Antiplatelet Therapy

(2014) Antonio Colombo et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial

(2014) Jean-Philippe Collet et al.   LANCET

Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents

(2014) Laura Mauri et al.   NEW ENGLAND JOURNAL OF MEDICINE

Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation

(2013) Cheol Whan Lee et al.   CIRCULATION

Clinical Outcomes With Bioabsorbable Polymer- Versus Durable Polymer-Based Drug-Eluting and Bare-Metal Stents

(2013) Tullio Palmerini et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting

(2012) Marco Valgimigli et al.   CIRCULATION

A New Strategy for Discontinuation of Dual Antiplatelet Therapy

(2012) Byeong-Keuk Kim et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents

(2011) Hyeon-Cheol Gwon et al.   CIRCULATION

Clinical, Angiographic, and Genetic Factors Associated With Early Coronary Stent Thrombosis

(2011) Guillaume Cayla et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Impact of the Everolimus-Eluting Stent on Stent Thrombosis

(2011) Usman Baber et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Duration of Dual Antiplatelet Therapy after Implantation of Drug-Eluting Stents

(2010) Seung-Jung Park et al.   NEW ENGLAND JOURNAL OF MEDICINE

Drug-Eluting Stent Thrombosis in Routine Clinical Practice

(2009) John M. Lasala et al.   Circulation-Cardiovascular Interventions

Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial

(2009) Roxana Mehran et al.   LANCET